Highlights Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.6142 ^USD	+4.92%		+0.69%	-56.44%

May. 29	Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch	CI
May. 15	Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch	May. 29	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	May. 14	MT
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	May. 14	MT
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication	May. 14	MT
Lemonaid Health, Inc. Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals	May. 14	CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	Apr. 23	MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	Apr. 23	CI
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	Apr. 16	CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	Apr. 02	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	Feb. 14	CI
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study	Jan. 17	CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status	Dec. 12	CI
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider	Dec. 05	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)	23-10-30	CI
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA	23-10-19	CI
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label	23-10-04	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Highlights

Filters